Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective
Hepatology International · 2024-10 · 18 (S2) · 959-976
DOI: 10.1007/s12072-024-10663-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hepatology International, online erschienen am 08.05.2024. Verfasst von Shelley E Keating und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia. s.keating@uq.edu.au. Hauptthemen laut MEDLINE: Exercise. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Queensland.
Abstract (Originalsprache)
Introduction
The prevalence, health and socioeconomic burden of metabolic dysfunction-associated fatty liver disease (MAFLD) is growing, increasing the need for novel evidence-based lifestyle approaches. Lifestyle is the cornerstone for MAFLD management and co-existing cardiometabolic dysfunction. The aim of this review was to evaluate the evidence for lifestyle management of MAFLD, with a specific lens on 24-hour integrated behaviour and provide practical recommendations for implementation of the evidence.
Results
Weight loss ≥ 7–10% is central to lifestyle management; however, liver and cardiometabolic benefits are attainable with improved diet quality and exercise even without weight loss. Lifestyle intervention for MAFLD should consider an integrated ‘24-h’ approach that is cognisant of diet, physical activity/exercise, sedentary behavior, smoking, alcohol intake and sleep. Dietary management emphasises energy deficit and improved diet quality, especially the Mediterranean diet, although sociocultural adaptations to meet preferences should be considered. Increasing physical activity and reducing sedentary behavior can prevent MAFLD, with strongest evidence in MAFLD supporting regular structured moderate–vigorous aerobic exercise for 150–240 min/week. Resistance training in addition to aerobic exercise should be considered and prioritised for those who are losing body mass via diet and/or pharmacological approaches and those with sarcopenia, to minimise bone and lean mass loss. Limited evidence suggests that sleep is important for MAFLD prevention. Emerging novel approaches to diet and exercise may address some of the key barriers to behaviour change (e.g. lack of time, access to resources and social support). Future Directions Large-scale multidisciplinary trials in people with MAFLD with long-term follow-up, that can be scaled up into mainstream healthcare, are required. Future management guidelines should consider the heterogeneity of MAFLD and specialised models of care that coordinate the health workforce to manage the increased and growing MAFLD population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia. s.keating@uq.edu.au.
- Kalinga Institute of Medical Sciences (KIMS), Bhubaneshwar, India.
- Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Förderung
- The University of Queensland
Zitieren
APA
Keating, S. E., Chawla, Y., De, A., & George, E. S. (2024). Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective. Hepatology International, 18(S2), 959-976. https://doi.org/10.1007/s12072-024-10663-9
Vancouver
Keating SE, Chawla Y, De A, George ES. Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective. Hepatology International. 2024;18(S2):959-976. doi:10.1007/s12072-024-10663-9
BibTeX
@article{Keating2024,
author = {Keating, Shelley E and Chawla, Yogesh and De, Arka and George, Elena S},
title = {Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective},
journal = {Hepatology International},
year = {2024},
volume = {18},
number = {S2},
pages = {959--976},
doi = {10.1007/s12072-024-10663-9}
}
EUVIMED